We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Soligenix Inc | NASDAQ:SNGX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -9.65% | 4.68 | 4.50 | 4.60 | 5.33 | 4.2901 | 5.10 | 145,802 | 00:30:48 |
Key Highlights from the Interview:
Soligenix plans to initiate patient enrollment in the confirmatory FLASH 2 study with HyBryte™ by the end of 2024. The company continues to explore the potential of HyBryte™ in treating other dermatological conditions such as psoriasis, where it has a Phase 2 study ongoing, demonstrating its commitment to expanding treatment options for patients with skin diseases.
For the full interview, watch the video here: https://youtu.be/R8khcNmj9ZQ?si=fXPpQrgPhTJVL1Hx
Read the latest interview with Dr. Ellen Kim on Soligenix’s promising Phase 3 FLASH trial here: https://prismmarketview.com/soligenixs-hybryte-lighting-the-way-towards-commercial-success-with-promising-flash-study-results/
About SoligenixSoligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's Disease.
Our Public Health Solutions business segment includes development programs for RiVax®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
DisclaimerThis communication was produced by PCG Digital Holdings, LLC, an affiliate of PCG Advisory Inc., (together "PCG"). PCG is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. PCG may be compensated by respective clients for publicizing information relating to its client's securities. See www.pcgadvisory.com/disclosures.
PCG Digitalinfo@pcgadvisory.com646-863-6341
A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/2e857033-bd5f-49ed-bbe1-ef6adf88a6a6
1 Year Soligenix Chart |
1 Month Soligenix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions